Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs-Reference-Cited by-同舟云学术

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Published:2020-06-23 Issue:7 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jeon Sangeun¹,Ko Meehyun¹,Lee Jihye¹,Choi Inhee²,Byun Soo Young³,Park Soonju³,Shum David³,Kim Seungtaek¹

Affiliation:

1. Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea

2. Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea

3. Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea

Abstract

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC 50 s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects.

Funder

National Research Foundation of Korea

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00819-20

Reference14 articles.

1. A pneumonia outbreak associated with a new coronavirus of probable bat origin

2. Estimating the risk of 2019 Novel Coronavirus death during the course of the outbreak in China, 2020

3. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia